瑞士最大的生物科技公司Actelion股价下跌8.6%，此前该公司生产的内皮素受体拮抗剂克拉生坦没有达到研发的主要目标。

Actelion Ltd., the largest Swiss biotechnology company, sank 8.6 percent after its clazosentan medicine didn’t meet the main goal of a study.

youdao

并且躯干拮抗肌的起始潜伏期随着目标的距离增加而增加，重量的加重而减少。

Further, the onset latency of the antagonist trunk muscles increased with target distance, but decreased with target load.

youdao

这篇文献回顾的目标是探讨钙离子拮抗剂是否可以降低缺血性中风后的死亡或依赖性。

To determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke.

youdao